PT - JOURNAL ARTICLE AU - Sadik Hasan Shuvo TI - COVID 19 in Bangladesh: Assumption of possible infection and death AID - 10.1101/2020.05.17.20104562 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.17.20104562 4099 - http://medrxiv.org/content/early/2020/05/24/2020.05.17.20104562.short 4100 - http://medrxiv.org/content/early/2020/05/24/2020.05.17.20104562.full AB - It is a painful job to predict the death of people. But sometimes it is important to predict the future and concern the government. A furious future is waiting for Bangladesh.Objective Objective of the study is to assume the number of positive case and death till 30th December, 2020 in Bangladesh.Study design This study was designed with systematic review and data analysis.Method The study was completed by analyzing data available on website. First COVID 19 case in Bangladesh was identified on 8th March. Analyzing the data increasing rate/common ratio of infection and death has been identified. Then this common ratio has been used in the formula of multiplication series (at decreasing rate). Data of China, Iran, Italy and the USA was also analyzed to assume how the death and case number increased. Social issues of Bangladesh were also analyzed. Considering all these the assumption was made.Result It has been assumed that by the 43rd week (on 30th December, 2020) of first identification the total case can be 15640747 and total death can be 638769 by 30 December, 2020. As this is an assumption this can be true, partially true or false. But the base of assumption is strong enough so the possibility of being true or nearly true is higher.Policy Suggestion Government should choose properly one between two options. Either government should declare curfew or let people lead normal life for the purpose of herd immunity. A very weak lockdown for a long time doesn’t make any sense.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes, data is available